vimarsana.com

Latest Breaking News On - Specialty medicines - Page 1 : vimarsana.com

20 Biggest Publicly Traded Biotech Companies

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook - GSK (NYSE:GSK)

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix. Expectations soar with raised 2024 EPS and sales forecasts.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.